|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the Clinical Research Division of the Fred
Hutchinson Cancer Research Center, the University of Washington School
of Medicine, and the Veteran's Affairs Medical Center, Seattle, WA.
The bcr-abl chimeric messenger RNA is
frequently detected in chronic myeloid leukemia (CML) patients after
bone marrow transplantation. It was previously reported that
the relapse risk of bcr-abl detection 6 to 12 months after transplantation was greater than 40%. This risk decreased
as the time between transplantation and detection increased. To further
define the relapse risk associated with bcr-abl molecular
detection in "late" CML survivors, 379 consecutive CML patients
alive at 18 months after transplantation or later were studied. Ninety
of 379 patients (24%) had at least one positive bcr-abl
test 18 months after transplantation or later; 13 of 90 bcr-abl-positive patients (14%) and 3 of 289 bcr-abl-negative patients (1.0%) relapsed. The median
time from bcr-abl detection to relapse was 916 days (range,
251-2654 days). The hazard ratio of relapse associated with
bcr-abl detection was 19.2 (P < .0001). The
stage of disease, chronic graft-versus-host disease, and the donor type did not alter the association between bcr-abl
and relapse. Quantification of bcr-abl was performed on 344 samples from 85 bcr-abl-positive patients by means of a
real-time quantitative reverse transcriptase-polymerase chain reaction
assay. The median bcr-abl change of patients who relapsed
was significantly greater than those that remained in remission
(P = .002). The median bcr-abl level at
relapse was 40 443 bcr-abl copies per µg RNA (range, 960-299 552). Of 73 bcr-abl-positive patients who failed
to relapse, 69% had only one positive test at a median of 24 copies
bcr-abl per µg RNA. The detection of bcr-abl
is common following transplantation. The prognostic significance of a
qualitative bcr-abl can be refined by quantitative assays
and thus may target patients who would benefit from early intervention.
(Blood. 2001;98:1701-1707) The genetic hallmark of chronic myeloid leukemia
(CML) is the Philadelphia chromosome (Ph), which occurs in at least
90% of cases.1,2 The reciprocal translocation between
chromosomes 9 and 22 places the 5' regulatory domains of the
BCR gene from chromosome 22 in juxtaposition with the 3'
tyrosine kinase domains of ABL from chromosome 9. This unique gene
fusion leads to the expression of chimeric bcr-abl messenger
RNA (mRNA) and the production of functional BCR-ABL fusion
protein.3 The chimeric bcr-abl mRNA is an
attractive target for monitoring minimal residual disease (MRD) by
reverse transcriptase-polymerase chain reaction (RT-PCR) assays.
Several studies have examined the significance of bcr-abl molecular detection after bone marrow transplantation (BMT). The detection of bcr-abl molecular disease is strongly
associated with relapse, though not absolutely
predictive.4-8 The significance of bcr-abl
positivity in CML is influenced by the time at which the patient is
tested after transplantation, the type of transplant, and the frequency
of testing.6,8-10 We previously reported that a single
positive assay for bcr-abl after transplantation was associated with an elevated risk of relapse.8 The
detection of bcr-abl at 6 to 12 months after BMT was
associated with a 42% risk of relapse at a median of 200 days from the
first PCR-positive result, as opposed to a 3% risk of relapse in
PCR-negative patients. This risk was greater for recipients of matched
related compared with unrelated donor transplants. The relative risk of
relapse associated with bcr-abl detection was approximately
30, even after clinical variables associated with relapse, such as
phase of disease and graft-versus-host disease (GVHD) status, were
controlled for. Because of this strong association, we initiated an
intervention trial treating those patients with bcr-abl
detected 6 to 12 months after BMT.
However, the significance of bcr-abl detection is less
evident when the detection occurs a longer period of time after
transplantation. Many CML patients persist with bcr-abl for
years after marrow transplantation. We found that 25% of patients
tested more than 36 months after BMT were bcr-abl positive,
and only 10% of these relapsed. These data were supported by Costello
et al,11 who found that 66 of 117 patients (56%) were
bcr-abl positive more than 36 months after BMT, but only 8%
relapsed. In addition, Van Rhee et al12 reported 19 patients in complete remission for more than 10 years after BMT, 2 of
whom were still positive for bcr-abl. A semiquantitative
assay demonstrated that bcr-abl transcript levels were very
low in these patients. In summary, these data suggest that molecular
relapse in CML patients years after BMT may not necessarily be a
harbinger of relapse, and these patients with MRD may thus not be
appropriate candidates for therapeutic intervention.
Since the significance of "late" bcr-abl detection is
unclear, we have followed such patients without intervention. To
further understand the significance of molecular relapse, we examined the prevalence of bcr-abl positivity in CML patients
surviving without cytogenetic or hematologic relapse at least 18 months after transplantation. Furthermore, since the predictive value of
bcr-abl detection in CML may be strengthened by
quantification of the bcr-abl expression,13-15
we performed quantification of bcr-abl burden by a real-time
fluorogenic assay to study the kinetics of bcr-abl emergence
in patients who relapsed compared with those with molecular disease but
no other evidence of disease.
Patients
Transplant regimen
Sample preparation RNA isolation from leukocytes from fresh bone marrow and peripheral blood samples was performed by Trizol extraction per manufacturer's protocol (Gibco BRL, Rockville, MD). Aliquots from the RNA were used for the detection of bcr-abl and the control 2 microglobulin mRNA (2µ).
RT-PCR for bcr-abl A 2-step, nested RT-PCR was used to amplify the chimeric bcr-abl mRNA, as previously described.8 The nucleotide sequences of the PCR primers used in bcr-abl amplification are listed in Table 1. For all PCR reactions a 10 5 and 106
dilution of an Amplichek BCR/ABL-positive CML control RNA
(BioRad, Hercules, CA) into the Amplichek BCR/ABL-negative RNA served
as the positive controls. Negative controls included a no-RNA PCR mix
("blank") and the Amplichek negative control RNA. A separate amplification of 2µ was used as a control of RNA integrity and was
performed as previously described.8 Precautions to
eliminate PCR carryover contamination included separate rooms for
pre-PCR and amplification procedures, aerosol-resistant pipette tips, and no-nucleic acid PCR reactions as negative controls in all PCR
amplification reactions.19
Quantitative RT-PCR The 5' exonuclease-based fluorogenic real-time RT-PCR of bcr-abl and2µ was performed in single tubes in an ABI Prism
7700 sequence detector (PE Applied Biosystems, Foster City, CA).
Quantification was performed on samples that were qualitatively
positive. The initial qualitative assay allowed for the determination
of the b2a2 or b3a2 bcr-abl breakpoints. In the quantitative
PCR (Q-PCR) assay, different bcr primers were used,
depending on the bcr breakpoint, in order to generate PCR
products in the optimal size range. Thus, the Q-PCR assay yielded an
85-base pair (bp) product for the b2a2 bcr-abl breakpoint
and an 84-bp product for the b3a2 breakpoint. The amplification product
for the 2µ gene was 70 bp.
In the Q-PCR assay, 100 nmol/L of a template-specific (either
bcr-abl or The sequences of the primers and probes used for the bcr-abl
and Collection and analysis of data The fluorescent emission data resulting from the amplification of target RNA was stored in real time during the run by the Prism 7700 and was analyzed following the completion of PCR. For each sample, the change in the fluorescence signal intensity from background, Rn, was
calculated for each RT-PCR cycle. The cycle threshold (Ct)
was defined at the cycle at which the fluorescence signal from the
RT-PCR reaction crosses a defined fluorescence threshold level. In
order to construct a standard curve, the Ct can be adjusted
(Ct') to optimize the relationship of the Ct
and the initial starting amount. The curve of Ct' vs the
log of the target amount has an optimal correlation coefficient
(r2) of 1.0. Since PCR should proceed as an exponential
amplification, the theoretical slope of this line should be 3.32; ie,
each log of target dilution should be separated by 3.32 cycles of
the PCR.
Calculation of bcr-abl messages To calculate the amount of unknown bcr-abl messages in a given sample, a standard curve of bcr-abl was created, with the use of the BCR/ABL-positive Amplichek cell line. RNA from the Amplichek CML cell line underwent serial log dilution into Amplichek negative cell line, ranging from 100 ng to 1 pg of Amplichek control RNA. In addition, a standard of fresh Amplichek positive RNA was diluted in water from 100 ng to 1 pg, and amplified with2µ primers.
Unknown samples had equal volumes of RNA subjected to amplification
with bcr-abl and The reproducibility of the assay was investigated several ways. First,
to evaluate the intra-experiment variation, 10 replicated dilution
series of the Amplichek CML cell line were mixed into a background of
Amplichek negative RNA, and Q-PCR was performed on all samples
simultaneously. The coefficient of variation (CV) in the Ct
value for all dilutions was then calculated for both the bcr-abl
and Definition of positive and negative RT-PCR assays The RT-PCR assays were performed without knowledge of the patient's cytogenetic results or hematologic remission status. A positive bcr-abl test required a correct size bcr-abl PCR product as well as negative blank and negative RNA control amplifications. A negative assay required the absence of a bcr-abl PCR product as well as no amplification of the blank and negative controls, successful amplification of the 105 diluted Amplichek positive control, and a successful
2µ RT-PCR amplification. If a positive or negative control did not
amplify as expected, the entire panel of patient samples done in that amplification batch was discarded and the assay repeated.
Definition of outcomes Relapse was defined by hematologic and cytogenetic criteria. Cytogenetic relapse was defined as 5 or more metaphases positive for the Ph at any point in time or the presence of any Ph on 2 successive cytogenetic evaluations at least 6 months apart. Patients were classified as being bcr-abl positive or bcr-abl negative at the time of sampling. A patient who had positive bcr-abl results concurrently with a sample that showed hematologic or cytogenetic relapse was classified according to the bcr-abl status at the last test prior to relapse. Patients were excluded from statistical analyses if they had evidence of hematologic or cytogenetic relapse simultaneously to, or before, their first bcr-abl assay.Statistical methods The hazard of relapse according to bcr-abl status was estimated by considering bcr-abl status as a time-dependent covariate in a Cox regression model,20 and the hazard ratio was estimated by taking the ratio of the hazards. The data were also considered as being left-truncated so that a patient did not contribute to the regression analysis until the first PCR test more than 18 months after transplantation occurred. At this time, the time-dependent covariate for bcr-abl status took on the value "1" if the bcr-abl test was positive and "0" otherwise. The value of the time-dependent covariate remained the same until the next bcr-abl test, at which time its value was determined as above. Any bcr-abl samples taken within 14 days of the date of relapse were not included in the regression models, as these were considered to be simultaneous with relapse. Multivariable regression models were fit by including various factors known to be associated with relapse, such as phase of disease, type of transplant, and presence or absence of chronic GVHD. Patients who died without relapse were censored at the time of death for purposes of estimating the hazard of relapse in regression models. The probability of relapse was estimated with a cumulative incidence estimate,21 where death without relapse was considered a competing risk.In order to assess the impact of quantitative bcr-abl testing, we considered all bcr-abl tests after transplantation among patients who had at least one bcr-abl-positive test more than 14 days prior to relapse and 18 months or more following transplantation. To test whether the burden of disease increased at a faster rate among those patients who relapsed compared with those who had not relapsed, 2 approaches were taken. In the first, a generalized estimating equation (GEE) model was fit,22 and the slope from the regression line of the logarithm of bcr-abl level on days after transplantation was estimated among patients who relapsed and among those who had not. The resulting slopes were then compared. In the second approach, a slope was estimated from each individual patient among the groups of patients who relapsed and those who had not. The average slope among those who relapsed was then compared with the average slope among those who did not relapse by means of the Wilcoxon rank-sum test. All P values are 2-sided and those from the regression model were estimated from the Wald test. The data were "locked" for analysis on April 1, 2000.
Patient characteristics The clinical characteristics of the 379 patients included in these analyses are shown in Table 2. The median age of the patients was 36 years (range, 5-61 years). The majority (204 of 379; 54%) received bone marrow from an allogeneic HLA-matched related donor; in 130 of 379 cases (34%), a matched unrelated donor was used for the transplant. The rest of the patients received transplants from HLA-mismatched or syngeneic donors. The vast majority of transplants (317 of 379; 84%) were performed in first chronic phase.
In sum, 947 informative samples were evaluated for the presence of bcr-abl by qualitative RT-PCR. The median number of assays per patient was 2 (range, 1-14). Forty percent of the patients had only one sample taken; 24% had 2 samples taken; 15% had 3; and 21% had 4 or more samples obtained and assayed. The median time from the first bcr-abl assay to either relapse or last contact was 12.2 months (range, 0-103.8 months). Test characteristics Over the study period, the qualitative bcr-abl test had a sensitivity and specificity of 91% and 97%, respectively, at a dilution level of 1:105. Samples were quantified by means
of the real-time "Taqman" assay. The assay revealed linear
detection across 5 logs of input RNA. The detection limit was 1 to 10 pg of Amplichek bcr-abl positive in a 1-µg background of
Amplichek negative RNA. The quantitative assay for 2µ was also
log-linear across 5 logs of input RNA, with a sensitivity limit of 1 pg RNA.
Ten replications of a single dilution series were performed, and the
median CV for the b3a2 bcr-abl assay across 5 logs of dilutions was 1.4% (range, 1.2%-5.6%). Next, we examined the
reproducibility of the assay from day to day by calculating the
Ct across all dilutions from 10 different runs. The CVs
ranged from 2% to 9% for both the b3a2 and b2a2 bcr-abl
assays and from 3% to 8% for the Prevalence of bcr-abl molecular relapse The prevalence of bcr-abl positivity is shown in Table 3. Overall, 90 of 379 patients (24%) tested positive at least once. Matched related transplants had a higher prevalence of positive tests (57 of 204; 28%) than patients receiving transplants from an unrelated donor (23 of 130; 18%). The proportion of patients testing positive was similar in those receiving transplants while in chronic phase (81 of 317; 26%), accelerated phase (7 of 42; 17%), and blast crisis or second chronic phase (2 of 20; 10%).
In 605 cases, peripheral blood and bone marrow were simultaneously analyzed, each providing interpretable results. In 91% of cases, the results of blood and marrow were concordant. In 6% of cases, marrow was positive for bcr-abl while blood was negative, and in 3% of cases, marrow was negative for bcr-abl while blood was positive. Risk of relapse in bcr-abl-positive patients The relapse experience of these patients is also shown in Table 3. Overall, 16 of 379 patients relapsed. Of the 90 patients who ever had a positive bcr-abl assay, 13 relapsed (14%). Of the 289 patients with persistently negative bcr-abl assays, 3 relapsed (1.0%). The median time of relapse in bcr-abl-positive patients was 916 days after their first positive assay (range, 251-2654 days). The median time to relapse in the 3 bcr-abl-negative patients who later relapsed was 250 days (range, 105-3011 days). Overall, the unadjusted hazard ratio (HR) of relapse for bcr-abl positivity compared with negativity was 19.2 (95% confidence interval [CI], 5.4-68.3; P < .0001).The cumulative incidence of relapse for bcr-abl-positive
patients is shown in Figure 1. The
probability of relapse 3 and 5 years following first bcr-abl
positivity was 19% (95% CI, 6%-32%) and 29% (95% CI, 12%-46%),
respectively (Figure 1). The probability of relapse among patients
undergoing a related versus an unrelated transplant was similar (Figure
2).
Multivariable analysis Clinical features potentially associated with relapse were added individually to bcr-abl qualitative status (Table 4). Phase of disease (chronic vs other), donor type (matched related vs mismatched or unrelated), and chronic GVHD (presence vs absence) were each added to the regression model containing only bcr-abl status. As noted above, the unadjusted HR of relapse for bcr-abl patients compared with bcr-abl patients was 19.2 (P < .0001). The addition of phase, donor type, and chronic GVHD did not appreciably alter the HR of relapse associated with bcr-abl, and none of these factors were statistically significantly associated with relapse after the bcr-abl status was factored in.
Quantitation of bcr-abl and relapse In total, 344 samples from 85 bcr-abl patients were available for quantification. The correlation of bcr-abl levels (copies per µg RNA) between 150 pairs of peripheral blood and bone marrow samples was good (Pearson correlation coefficient, 0.65; Spearman rank correlation coefficient, 0.91).Seventy-six of the 85 patients had at least 2 quantitative tests available, and 10 of these patients ultimately relapsed. The logarithm of PCR was regressed on days after transplantation for each patient, and the resulting regression line estimated. Included in these curves were all bcr-abl values, including those before 18 months after BMT. Nine of 10 patients (90%) who relapsed had a positive bcr-abl slope, compared with 25 of 66 patients (38%) who did not relapse. The slope of the patients who relapsed was, on average, higher compared with the slope among patients who did not relapse (P = .002, Wilcoxon rank-sum test). The association of bcr-abl kinetics and relapse was also explored by averaging bcr-abl slopes over the entire population rather than across individual patients. This analysis used GEEs, which allow one to estimate the statistical significance of the difference observed between the slope of the regression lines among patients who relapsed and those who did not, taking into account the (potential) multiple measurements per patient. This analysis does not require that each patient have at least 2 measurements, as did the analysis that calculated a slope for each individual. Eleven of the 85 patients ultimately relapsed, and 74 have not. The slope calculated among the 11 patients who relapsed is statistically significantly higher than the slope calculated among the remaining 74 patients who did not relapse (P = .03). Figure 3 shows the individual
bcr-abl levels from the time of transplantation for 10 patients who relapsed. The median bcr-abl level at the time
of cytogenetic relapse was 40 443 copies per µg RNA. The lowest
level of bcr-abl found at cytogenetic relapse was 960 copies
per µg RNA. The curves demonstrate a fairly steady progression of
increasing bcr-abl level prior to relapse with 2 exceptions.
Patient A was an unrelated donor patient who underwent his
transplantation for blast crisis. This patient had a bcr-abl level of 2595 bcr-abl copies per µg RNA on day 187 after
transplantation. The course was then complicated by an extramedullary
relapse, which was treated with 6 cycles of chemotherapy. During this
time, the bcr-abl fell. Approximately 9 months after
finishing chemotherapy, the patient experienced both a medullary and an
extramedullary relapse. A second patient, "G," developed
cytogenetic evidence of the Ph at day 80, which disappeared, with an
accordant decrease in bcr-abl level, with the
discontinuation of immunosuppression and the appearance of GVHD. At the
1-year follow-up, the GVHD had quieted, and bcr-abl
increased over the next 2 years, until relapse.
Seventy-three patients had at least one bcr-abl-positive
assay but never relapsed. In total, 308 additional assays were
performed on these patients (median, 4 assays per patient; range,
1-12), and 109 (35%) were positive at least once for
bcr-abl. Fifty of 73 patients had only one positive assay
(69%); 14 of 73 (19%) had 2 positive assays; and 9 of 73 (12%) had 3 or more assays positive for bcr-abl. Quantitative values for
these patients who did not relapse tended to be quite low. In these
samples, 62% had fewer than 100 copies of bcr-abl per µg
RNA; 23% between 100 and 1000 copies; and 15% more than 1000 copies.
In retrospect, these high values were caused by normalization of the
bcr-abl levels by very low amounts of the control
The detection of bcr-abl mRNA following transplantation is common and is most strongly associated with relapse shortly after transplantation and in the T-cell-depleted setting.6,8,10 However, a significant number of patients have evidence of molecular relapse years after transplantation. The significance of late molecular relapse in these CML patients is unclear. Since therapeutic intervention with interferon or donor leukocyte infusion can induce remission in patients who undergo a cytogenetic relapse,23-25 but at the cost of morbidity and mortality, it is of interest to determine the relationship of molecular relapse and outcome. Should all patients who are in molecular relapse be treated? Should these patients be followed closely, but without therapeutic intervention? Or should intervention be based on quantification of bcr-abl level? To address these issues, we studied 379 patients who had survived relapse-free at least 18 months after BMT. We found that bcr-abl positivity occurred in a quarter of all patients, and the relative risk of relapse for bcr-abl-positive patients compared with bcr-abl-negative patients was approximately 20. Clinical factors, such as phase of disease, type of transplant, and GVHD, did not influence the association of bcr-abl positivity with relapse. However, the absolute risk of relapse in those patients with molecular relapse was modest, with a 19% 3-year cumulative incidence estimate following their first positive bcr-abl assay. The application of a quantitative assay appeared powerful in distinguishing patients destined to relapse from those with persistent disease displaying more dormant bcr-abl growth kinetics. In our previous study, we noted that in patients tested 6 to 12 months after BMT, recipients of related and unrelated marrow had a similar prevalence of positive bcr-abl assays (approximately 25%), yet related transplant recipients had a much higher rate of relapse (60% vs 10%). In the current study, which focused on patients who survived without relapse for at least 18 months, the situation is apparently different, as donor type and GVHD had no statistically significant impact on relapse. It may be that this finding reflects the time needed for the unrelated donor patients to develop immune tolerance, which, while obviating GVHD, might also diminish any graft-versus-leukemia effect. Thus with immune tolerance, the risk of relapse associated with molecular relapse in the unrelated donor patients mirrors that of the related donor transplants. The data suggest that a qualitative positive test alone should be interpreted with caution, rather than automatically triggering a therapeutic intervention. For example, if peripheral blood is routinely monitored, a positive qualitative test could signal an opportune time to test bone marrow for cytogenetic evidence of relapse. Alternatively, quantification of bcr-abl might be performed for those patients with a qualitative positive test to further define burden of disease and risk of subsequent cytogenetic or hematologic relapse. In this study, the slope of bcr-abl change was significantly steeper in those patients destined to relapse compared with those who did not. This observation is in keeping with prior published work demonstrating the power of PCR quantification.13-15 Indeed, although our method of Q-PCR was technically different from that used in other methods demonstrating the association of increasing copy number and relapse, the rate of kinetic bcr-abl increase and the levels of bcr-abl at relapse in this present study were quite similar to those in previous studies.13 In addition, the sensitivity and reproducibility of the real-time Q-PCR employed in our study are consistent with those previously published.26-28 Finally, recently Olavarria et al29 studied 138 CML patients "early" (3 to 5 months) after transplantation and showed that the bcr-abl level was highly correlated with relapse. Patients with no evidence of bcr-abl had a 9% risk of subsequent cytogenetic or hematologic relapse, whereas patients defined as having a low burden of disease (fewer than 100 bcr-abl transcripts per µg RNA) or a high level of transcripts (more than 100 copies per µg) had a cumulative relapse rate of 30% and 74%, respectively. These results are consistent with the high risk of relapse associated with early qualitative bcr-abl positivity at 6 months after BMT formerly reported.5,8 The results from Olavarria et al on bcr-abl quantification in early posttransplantation patients thus nicely complement the data presented in this manuscript on the risks associated with late bcr-abl detection, painting a more complete landscape of the prevalence and significance of minimal residual disease detection in this setting. Our study admittedly is potentially flawed in the sense that not all patients provided assays at the same time point after transplantation. The upshot of this imperfect sampling is that the observed association of bcr-abl positivity with an increased hazard of relapse may be biased. The precise nature of this bias is impossible to know, but one might suspect that patients doing well would be less likely to be tested as frequently as patients thought to be doing poorly. Although we cannot discount the potential for such bias, our data do not suggest an obvious effect of this type. Among patients who have not relapsed, 40% received only one PCR test, 23% received 2 tests, 15% received 3 tests, and the remaining 22% received 4 or more tests. Among the patients who relapsed, 44% received only 1 test, 19% received 2 tests, 25% received 3 tests, and 13% had 4 or more tests. The average number of tests among patients who have and have not relapsed was not statistically significantly different (P = .64), and in fact, the average number among those who have not relapsed was slightly higher. Our current study, coupled with previous work by us and others, demonstrates that many patients continue to have molecular evidence of disease for years, yet fail to relapse. This persistence of molecular disease (dormancy) has also been seen in acute myelogenous leukemia (AML), and acute lymphoblastic leukemia (ALL).30-32 Indeed, most patients with t(8;21) AML have been found to have molecular evidence of the AML/ETO translocation after years in remission.30,31 In addition, pediatric ALL patients who relapsed after more than 10 years of remission have been found to relapse with a leukemia possessing the same clonal immunoglobulin heavy chain VDJ gene rearrangement as initially present at diagnosis.33 What is the mechanism of dormancy? One can imagine several nonmutually exclusive mechanisms, including the following: (1) prolonged immune surveillance; (2) the persistence of preleukemic clonal disease without the full complement of genetic lesions required for the development of frank malignancy; or (3) the presence of a secondary genetic lesion that may render the leukemic progenitor cells relatively quiescent. Regardless, it is likely that a functional "cure" of leukemia is not equivalent to the total eradication of all leukemic or preleukemic cells. The discovery of the mechanisms of dormancy may lead to inroads in defining what it takes to cure leukemia. There are obstructions to using bcr-abl testing to guide therapy, since technical issues of contamination, sensitivity, and specificity are hardly trivial.34 In addition, bcr-abl rearrangements have been described in normal adults, although at an abundance not detectable by standard RT-PCR assays used for MRD testing.35,36 Despite these caveats, it appears that bcr-abl detection is a significant clinical event. The rationale for determining MRD is the hope that early intervention may preclude eventual clinical relapse and improve survival. Proper intervention for bcr-abl molecular disease in CML is unknown, and such intervention should be offered only in a research setting. Only such careful study will tell whether the concept of early intervention for molecular relapse fulfills that promise.
Submitted September 19, 2000; accepted May 15, 2001.
Supported in part by National Institute of Health grants CA-18029 and CA-18221.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Jerald P. Radich, 1100 Fairview Ave N, D4-100, PO Box 19024, Seattle, WA 98109-1024; e-mail: jradich{at}fhcrc.org.
1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;14:97. 2. Shtivelman E, Lifshitz B, Gale RP, Cananni E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315:550-554[CrossRef][Medline] [Order article via Infotrieve]. 3. Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell. 1984;37:1035-1042[CrossRef][Medline] [Order article via Infotrieve].
4.
Kawasaki ES, Clark SS, Coyne MY, et al.
Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro.
Proc Natl Acad Sci U S A.
1988;85:5698-5702
5.
Hughes TP, Morgan GJ, Martiat P, Goldman JM.
Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of the polymerase chain reaction in predicting relapse.
Blood.
1991;77:874-878
6.
Roth MS, Antin JH, Ash R, et al.
Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after an allogeneic bone marrow transplant for chronic myelogenous leukemia.
Blood.
1992;79:276-282
7.
Miyamura K, Tahara T, Tanimoto M, et al.
Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients.
Blood.
1993;81:1089-1094
8.
Radich JP, Gehly G, Gooley T, et al.
PCR detection of the bcr-abl fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients.
Blood.
1995;85:2632-2638
9.
Pichert G, Roy DC, Goin R, et al.
Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
J Clin Oncol.
1995;13:1704-1713 10. Mackinnon S, Barnett L, Heller G. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation of chronic myeloid leukemia. Bone Marrow Transplant. 1996;17:643-647[Medline] [Order article via Infotrieve]. 11. Costello RT, Kirk J, Gabert J. Value of PCR analysis for long term survivors after allogeneic bone marrow transplant for chronic myelogenous leukemia: a comparative study. Leuk Lymphoma. 1996;20:239-243[Medline] [Order article via Infotrieve]. 12. Van Rhee F, Lin F, Cross NCP, et al. Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia. Bone Marrow Transplant. 1994;14:609-612[Medline] [Order article via Infotrieve].
13.
Lin F, van Rhee F, Goldman JM, Cross NCP.
Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation.
Blood.
1996;87:4473-4478
14.
Cross NCP, Lin F, Chase A, Bungey J, Hughes TP, Goldman JM.
Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation.
Blood.
1993;82:1929-1936 15. Lion T, Gaiger A, Henn T, et al. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon. Leukemia. 1995;9:1353-1360[Medline] [Order article via Infotrieve]. 16. Thomas ED, Clift A, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med. 1986;104:155-163.
17.
Clift RA, Buckner CD, Thomas ED, et al.
Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cylosphosphamide.
Blood.
1994;84:2036-2043 18. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;313:729-735. 19. Kwok S, Higushi R. Avoiding false positives with PCR. Nature. 1989;339:237-238[CrossRef][Medline] [Order article via Infotrieve]. 20. Cox DR, Oakes D. Analysis of Survival Data. London United Kingdom: Chapman and Hall; 1984. 21. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706[CrossRef][Medline] [Order article via Infotrieve]. 22. Zeger S, Liaug KY, Albert PS. Models of longitudinal data: a generalized estimation equation approach. Biometrics. 1988;44:1049-1060[CrossRef][Medline] [Order article via Infotrieve].
23.
Kolb HJ, Mittermuller J, Clemm C, et al.
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.
Blood.
1990;76:2462-2465
24.
Cullis JO, Jiang YZ, Schwarer AP, Hughes TP, Barrett AJ, Goldman JM.
Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation.
Blood.
1992;79:1379-1381
25.
Drogyski WR, Keever CA, Roth MS, et al.
Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose.
Blood.
1993;82:2310-2318 26. Mensink E, van de Locht A, Schattenberg A, et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol. 1998;102:768-774[CrossRef][Medline] [Order article via Infotrieve]. 27. Preudhomme C, Revillion F, Merlat A, et al. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a "real time" quantitative RT-PCR assay. Leukemia. 1999;13:957-964[CrossRef][Medline] [Order article via Infotrieve]. 28. Branford S, Hughes TP, Rudzski Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol. 1999;107:587-599[CrossRef][Medline] [Order article via Infotrieve].
29.
Olavarria E, Kanfer E, Szydlo R, et al.
Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia.
Blood.
2001;97:1560-1565 30. Maruyama F, Stass SA, Estey EH, et al. Detection of AML1/ETO fusion transcript as a tool for diagnosing t(8;21) positive acute myelogenous leukemia. Leukemia. 1994;8:40-45[Medline] [Order article via Infotrieve]. 31. Kusec R, Laczika K, Knobl P, et al. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia. 1994;8:735-739[Medline] [Order article via Infotrieve].
32.
Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DS, McClain KL, Zipf TF.
Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia.
N Engl J Med.
1997;336:317-323
33.
Vora A, Frost L, Goodeve A, et al.
Late relapsing childhood lymphoblastic leukemia.
Blood.
1998;92:2334-2337
34.
Federl S, Talpaz M, Kantarjian HM, Estrov Z.
Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
Blood.
1999;93:2755-2759
35.
Biernaux C, Loos M, Sels A, Huez G, Stryckmans P.
Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals.
Blood.
1995;86:3118-3122
36.
Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV.
The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.
Blood.
1998;92:3362-3367
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  S. Branford, L. Fletcher, N. C. P. Cross, M. C. Muller, A. Hochhaus, D.-W. Kim, J. P. Radich, G. Saglio, F. Pane, S. Kamel-Reid, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials Blood, October 15, 2008; 112(8): 3330 - 3338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Ross, D. B. Watkins, T. P. Hughes, and S. Branford Reverse Transcription with Random Pentadecamer Primers Improves the Detection Limit of a Quantitative PCR Assay for BCR-ABL Transcripts in Chronic Myeloid Leukemia: Implications for Defining Sensitivity in Minimal Residual Disease Clin. Chem., September 1, 2008; 54(9): 1568 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Press, C. Galderisi, R. Yang, C. Rempfer, S. G. Willis, M. J. Mauro, B. J. Druker, and M. W.N. Deininger A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response Clin. Cancer Res., October 15, 2007; 13(20): 6136 - 6143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Winn-Deen, B. Helton, R. Van Atta, W. Wong, J. Peralta, J. Wang, G. J. Tsongalis, D. Belloni, D. Chan, J. R. Eshleman, et al. Development of an Integrated Assay for Detection of BCR-ABL RNA Clin. Chem., September 1, 2007; 53(9): 1593 - 1600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. G. Oehler, T. Gooley, D. S. Snyder, L. Johnston, A. Lin, C. C. Cummings, S. Chu, R. Bhatia, S. J. Forman, R. S. Negrin, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia Blood, February 15, 2007; 109(4): 1782 - 1789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Steensma and R. E. Richard Myeloproliferative disorders ASH Self-Assessment Program, January 1, 2007; 2007(1): 172 - 227. [Full Text] [PDF]
|
|
|
|
|
|
T. Hughes, M. Deininger, A. Hochhaus, S. Branford, J. Radich, J. Kaeda, M. Baccarani, J. Cortes, N. C. P. Cross, B. J. Druker, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood, July 1, 2006; 108(1): 28 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Maziarz Transplantation for CML: lifelong PCR monitoring? Blood, May 15, 2006; 107(10): 3820 - 3820. [Full Text] [PDF]
|
|
|
|
|
|
B. N. Savani, K. Rezvani, S. Mielke, A. Montero, R. Kurlander, C. S. Carter, S. Leitman, E. J. Read, R. Childs, and A. J. Barrett Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia Blood, February 15, 2006; 107(4): 1688 - 1695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Apperley Managing the Patient with Chronic Myeloid Leukemia Through and After Allogeneic Stem Cell Transplantation Hematology, January 1, 2006; 2006(1): 226 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chu, H. Xu, N. P. Shah, D. S. Snyder, S. J. Forman, C. L. Sawyers, and R. Bhatia Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment Blood, March 1, 2005; 105(5): 2093 - 2098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Robien, C. M. Ulrich, J. Bigler, Y. Yasui, T. Gooley, B. Bruemmer, J. D. Potter, and J. P. Radich Methylenetetrahydrofolate Reductase Genotype Affects Risk of Relapse after Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia Clin. Cancer Res., November 15, 2004; 10(22): 7592 - 7598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Branford, Z. Rudzki, I. Parkinson, A. Grigg, K. Taylor, J. F. Seymour, S. Durrant, P. Browett, A. P. Schwarer, C. Arthur, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations Blood, November 1, 2004; 104(9): 2926 - 2932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Stone Optimizing Treatment of Chronic Myeloid Leukemia: A Rational Approach Oncologist, June 1, 2004; 9(3): 259 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rosti, G. Martinelli, S. Bassi, M. Amabile, E. Trabacchi, B. Giannini, D. Cilloni, B. Izzo, A. De Vivo, N. Testoni, et al. Molecular response to imatinib in late chronic-phase chronic myeloid leukemia Blood, March 15, 2004; 103(6): 2284 - 2290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. P. Hughes, J. Kaeda, S. Branford, Z. Rudzki, A. Hochhaus, M. L. Hensley, I. Gathmann, A. E. Bolton, I. C. van Hoomissen, J. M. Goldman, et al. Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia N. Engl. J. Med., October 9, 2003; 349(15): 1423 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Radich, T. Gooley, W. Bensinger, T. Chauncey, R. Clift, M. Flowers, P. Martin, J. Slattery, D. Sultan, and F. R. Appelbaum HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen Blood, July 1, 2003; 102(1): 31 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Nashed, K. W. Rao, and M. L. Gulley Clinical Applications of BCR-ABL Molecular Testing in Acute Leukemia J. Mol. Diagn., May 1, 2003; 5(2): 63 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Gallagher, B. Y. Yeap, W. Bi, K. J. Livak, N. Beaubier, S. Rao, C. D. Bloomfield, F. R. Appelbaum, M. S. Tallman, J. L. Slack, et al. Quantitative real-time RT-PCR analysis of PML-RARalpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129 Blood, April 1, 2003; 101(7): 2521 - 2528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Bock, U. Lehmann, and H. Kreipe Quantitative Intra-Individual Monitoring of BCR-ABL Transcript Levels in Archival Bone Marrow Trephines of Patients with Chronic Myeloid Leukemia J. Mol. Diagn., February 1, 2003; 5(1): 54 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Uzunel, J. Mattsson, M. Brune, J.-E. Johansson, J. Aschan, and O. Ringden Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation Blood, January 15, 2003; 101(2): 469 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kantarjian, M. Talpaz, J. Cortes, S. O'Brien, S. Faderl, D. Thomas, F. Giles, M. B. Rios, J. Shan, and R. Arlinghaus Quantitative Polymerase Chain Reaction Monitoring of BCR-ABL during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous Leukemia Clin. Cancer Res., January 1, 2003; 9(1): 160 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Melo, T. P. Hughes, and J. F. Apperley Chronic Myeloid Leukemia Hematology, January 1, 2003; 2003(1): 132 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Braziel, M. A. Shipp, A. L. Feldman, V. Espina, M. Winters, E. S. Jaffe, E. F. Petricoin III, and L. A. Liotta Molecular Diagnostics Hematology, January 1, 2003; 2003(1): 279 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Druker, S. G. O'Brien, J. Cortes, and J. Radich Chronic Myelogenous Leukemia Hematology, January 1, 2002; 2002(1): 111 - 135. [Abstract] [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
80°C,
then removed for quantification every 1 to 2 weeks for a total of 13 weeks. The ratio of bcr-abl to 
